TCGA-2F-A9KQ-01A-11R-A38B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 94.80946124
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.370
- BILE_ACID_METABOLISM+0.310
- PANCREAS_BETA_CELLS+0.300
- P53_PATHWAY+0.260
- TGF_BETA_SIGNALING+0.220
- HYPOXIA+0.210
- ADIPOGENESIS+0.190
- PROTEIN_SECRETION+0.190
- COAGULATION+0.160
- XENOBIOTIC_METABOLISM+0.160
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.580
- INTERFERON_GAMMA_RESPONSE-0.530
- ALLOGRAFT_REJECTION-0.500
- MYC_TARGETS_V2-0.450
- MYC_TARGETS_V1-0.360
- TNFA_SIGNALING_VIA_NFKB-0.340
- E2F_TARGETS-0.330
- INFLAMMATORY_RESPONSE-0.330
- IL6_JAK_STAT3_SIGNALING-0.320
- G2M_CHECKPOINT-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | aMVAC.P_003_TURBT_S220 | — | — | 0.819 |
| 2 | SRR8518184 | — | F | 0.812 |
| 3 | sclcCHTN02019_S70.txt | — | cohortSC | 0.810 |
| 4 | SRR25617843 | — | B | 0.803 |
| 5 | SRR8613754 | — | F | 0.784 |
| 6 | 35c6ff25-753c-4ebe-bbe7-2e7105d052e8 | — | — | 0.782 |
| 7 | C3L-02834 | — | cohortA1 | 0.779 |
| 8 | SRR8518290 | — | F | 0.772 |
| 9 | TCGA-B6-A1KI-01A-11R-A14M-07 | — | B | 0.770 |
| 10 | SRR29022834 | — | A | 0.766 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| MYOGENESIS | 0.060 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |